Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity
Jonathan C. Javitt, Gergana P. Zlateva, Stephanie R. Earnshaw, Andreas M. Pleil, Christopher N. Graham, Anita J. Brogan, Sonali N. Shah, Anthony P. Adamis
Dive into the research topics of 'Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity'. Together they form a unique fingerprint.